Ratings by Goldman Sachs (Asad Haider)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/26/2026 | Vaxcyte | PCVX | Maintain | Neutral (N/A) |
|
Details | ||
| 2/13/2026 | Royalty Pharma | RPRX | Maintain | Buy (N/A) |
|
Details | ||
| 2/5/2026 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 1/28/2026 | Abbvie | ABBV | Maintain | Neutral (N/A) |
|
Details | ||
| 1/23/2026 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 1/16/2026 | BioNTech | BNTX | Upgrade | Buy (Neutral) |
106.07 (101.50) |
-4.31% | Details | |
| 12/18/2025 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 11/6/2025 | Royalty Pharma | RPRX | Maintain | Buy (N/A) |
|
Details | ||
| 11/5/2025 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 10/8/2025 | Johnson & Johnson | JNJ | Maintain | Conviction Buy (N/A) |
|
Details | ||
| 9/30/2025 | Inova Technology, Inc. | INVA | New Coverage | Sell (N/A) |
19.03 (22.03) |
15.76% | Details | |
| 9/30/2025 | Royalty Pharma | RPRX | New Coverage | Buy (N/A) |
35.25 (45.41) |
28.82% | Details | |
| 9/22/2025 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 9/19/2025 | Johnson & Johnson | JNJ | Maintain | Conviction Buy (N/A) |
|
Details | ||
| 9/12/2025 | Vaxcyte | PCVX | New Coverage | Neutral (N/A) |
33.06 (59.29) |
79.34% | Details | |
| 7/17/2025 | NewAmsterdam Pharma Co NV | NAMS | New Coverage | Neutral (N/A) |
20.92 (29.86) |
42.73% | Details | |
| 7/17/2025 | Johnson & Johnson | JNJ | Maintain | Buy (N/A) |
|
Details | ||
| 7/10/2025 | Johnson & Johnson | JNJ | Maintain | Conviction Buy (N/A) |
|
Details | ||
| 6/3/2025 | Merck | MRK | Maintain | Buy (N/A) |
|
Details | ||
| 5/29/2025 | BioNTech | BNTX | New Coverage | Neutral (N/A) |
97.53 (106.07) |
8.76% | Details | |
| 4/28/2025 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 4/21/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Neutral (N/A) |
|
Details | ||
| 4/8/2025 | Merck | MRK | New Coverage | Buy (N/A) |
81.47 (115.79) |
42.13% | Details | |
| 4/8/2025 | Abbvie | ABBV | New Coverage | Neutral (N/A) |
186.96 (230.11) |
23.08% | Details | |
| 4/8/2025 | Bristol-Myers Squibb Co. | BMY | Downgrade | Neutral (Buy) |
55.30 (60.29) |
9.02% | Details | |
| 4/8/2025 | Eli Lilly | LLY | Upgrade | Buy (Neutral) |
738.21 (990.33) |
34.15% | Details | |
| 4/8/2025 | Pfizer | PFE | Downgrade | Neutral (Buy) |
22.97 (27.05) |
17.76% | Details | |
| 4/8/2025 | Johnson & Johnson | JNJ | Upgrade | Buy (Neutral) |
153.24 (240.40) |
56.88% | Details | |
| 12/14/2018 | ICON plc | ICLR | Downgrade | Buy (Conviction Buy) |
138.11 (318.08) |
130.31% | Details |
